Frequency of Pleural Mesothelioma in Mexican Women. Case Study
Main Article Content
Abstract
Introduction: Pleural mesothelioma is a rare and aggressive tumor, which is uncommon in women and requires further clinical characterization.
Methods: A retrospective study was conducted at the National Institute of Respiratory Diseases (January-December 2024), which included 21 women with a histological diagnosis.
Results: The mean age was 63.5 years, and 38% reported domestic exposure to asbestos. All patients presented with pleural effusion, 57% with hypoxemia, and more than half required emergency care. The diagnosis was obtained mainly through VATS, with a diagnostic yield of 100% in all modalities. The predominant histological subtype was epithelioid in 90% of cases, and all were classified as stage IV.
Conclusions: Pleural mesothelioma in women continues to be a late-diagnosed entity, with high clinical severity and frequently unrecognized exposure to asbestos. The constant presence of pleural effusion and the high proportion of stage IV patients highlight the priority of reinforcing diagnostic suspicion and timely access to highly cost-effective invasive methods, especially in contexts where domestic exposure may go unnoticed.
Downloads
Article Details
Section

This work is licensed under a Creative Commons Attribution 4.0 International License.
How to Cite
References
Hajj GNM, Cavarson CH, Pinto CAL, Venturi G, Navarro JR, De Lima VCC. Malignant pleural mesothelioma: an update. J Bras Pneumol 2021;e20210129. https://doi.org/10.36416/1806-3756/e20210129
Abbott DM, Bortolotto C, Benvenuti S, Lancia A, Filippi AR, Stella GM. Malignant pleural mesothelioma: Genetic and microenvironmental heterogeneity as an unexpected reading frame and therapeutic challenge. Cancers (Basel) 2020;12(5):1186. https://doi.org/10.3390/cancers12051186
Gopar-Nieto R, Cabello-López A, Juárez-Pérez CA, Haro-García LC, Jiménez Ramírez C, Aguilar-Madrid C. Actualización sobre la epidemiología, fisiopatología, diagnóstico y tratamiento del mesotelioma maligno pleural. Rev Med Inst Mex Seguro Soc 2016;54(6):770–6.
Muñoz E, Ramírez Ocaña D, Gutiérrez Cardo AL. Mesotelioma pleural maligno en adulto joven sin exposición conocida al asbesto. Arch Bronconeumol 2016;52(12):615–6. https://doi.org/10.1016/j.arbres.2016.02.010
Hemminki K, Försti A, Chen T, Hemminki A. Incidence, mortality and survival in malignant pleural mesothelioma before and after asbestos in Denmark, Finland, Norway and Sweden. BMC Cancer 2021;21:1189. https://doi.org/10.1186/s12885-021-08913-2
Panou V, Vyberg M, Meristoudis C, Hansen J, Bøgsted M et al. Non-occupational exposure to asbestos is the main cause of malignant mesothelioma in women in North Jutland, Denmark. Scand J Work Environ Health 2019;45(1):82–9. https://doi.org/10.5271/sjweh.3756
Barsky AR, Ahern CA, Venigalla S, Verma V, Anstadt EJ, Wright CM et al. Gender-based disparities in receipt of care and survival in malignant pleural mesothelioma. Clin Lung Cancer 2020;21(6):e583–91. https://doi.org/10.1016/j.cllc.2020.05.021
Husain AN, Colby T, Ordonez N, Krausz T, Attanoos R, Beasley MB et al.; International Mesothelioma Interest Group. Guidelines for pathologic diagnosis of malignant mesothelioma: 2012 update of the consensus statement. Arch Pathol Lab Med 2013;137(5):647–67. https://doi.org/10.5858/arpa.2012-0214-OA
Carbone M, Kanodia S, Chao A, Miller A, Wali A, Weissman D et al. Consensus report of the 2015 Weinman International Conference on Mesothelioma. J Thorac Oncol 2016;11(8):1246–62. https://doi.org/10.1016/j.jtho.2016.04.028
Schumann SO, Kocher G, Minervini F. Epidemiology, diagnosis and treatment of malignant pleural mesothelioma: A narrative review of literature. J Thorac Dis 2021;13(4):2510–23. https://doi.org/10.21037/jtd-20-2761
Wang H, Yang R, Liu D, Li W. Pleural effusion is an independent prognostic factor in patients with malignant pleural mesothelioma. Sci Rep 2025;15:392. https://doi.org/10.1038/s41598-024-84108-6
Davies HE, Mishra EK, Kahan BC, Wrightson JM, Stanton AE, Guhan A et al. Effect of an indwelling pleural catheter vs chest tube and talc pleurodesis for relieving dyspnea in patients with malignant pleural effusion: The TIME2 randomized controlled trial. JAMA 2012;307(22):2383–9. https://doi.org/10.1001/jama.2012.5535